GPC3 CAR-T cells for advanced liver cancer
Treatments studied
Part of Cancer, Digestive system clinical trials.
This trial tests a new type of immunotherapy called CAR-T cells that are designed to attack liver cancer cells with a specific protein (GPC3). The goal is to see if this treatment can help people with advanced liver cancer that hasn't responded to other treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 70 years old.
- You have advanced liver cancer (hepatocellular carcinoma) that has grown or not responded to standard treatments.
- Your tumor shows a protein called GPC3 (confirmed by a biopsy test).
- Your liver is functioning well enough (Child-Pugh class A or B).
- You are generally in good health (you can do most daily activities), and your blood counts, liver, kidney, heart, and lungs are within safe levels.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new treatment using your own immune cells, modified to better find and attack liver cancer cells. It is for people whose liver cancer has returned or spread and cannot be removed with surgery.
This trial tests a new cell therapy called SN301A for people with advanced liver cancer that has a specific protein (GPC3) on the tumor cells. The goal is to see if this treatment can help when other treatments have stopped working.
This early-phase study tests modified immune T cells (CAR T cells) to treat hepatocellular carcinoma (HCC), a type of liver cancer, when the tumor shows a marker called GPC3. It may help shrink tumors or slow cancer growth, especially after other treatments have stopped working.
This trial is testing a new treatment made from your own immune cells (called CT011 CAR-T cells) to see if it can lower the risk of liver cancer coming back after surgery. It is designed for people with advanced liver cancer that has spread into nearby blood vessels.
This trial tests an experimental cell therapy (TC-G203) for people with advanced solid tumors that have a specific protein called GPC3. It aims to see if this treatment is safe and effective for those who haven't responded to standard treatments.
This trial tests a new type of immune cell therapy, called CAR-T cells, that are engineered to target a protein called GPC3 found on liver cancer cells. It is for people with advanced liver cancer that has not responded to previous treatments.
Hear when a new Hepatocellular Carcinoma (HCC) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.